2-Methyl-3-(S-pyrrolidinothioxomethyl)thiopropanoic Acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Methyl-3-(S-pyrrolidinothioxomethyl)thiopropanoic Acid
• 英文别名: 2-Methyl-3-(pyrrolidine-1-carbothioylsulfanyl)propanoic acid
• 化学式: C₉H₁₅NO₂S₂
• 分子量: 233.356
• InChiKey: BRIWAQXIMBZMSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 甲基丙烯酸 在 二硫化碳 作用下， 以 水 为溶剂， 以73%的产率得到2-Methyl-3-(S-pyrrolidinothioxomethyl)thiopropanoic Acid
  参考文献：
  名称：

  Methods for preparing captopril and its analogues

  摘要：

  本发明涉及一种将口服血管紧张素转化酶（ACE）抑制剂的S-保护衍生物及其类似物的对映异构体混合物转化为其单独的光学分辨对映异构体组分的新方法。具体地，本发明涉及从外消旋前体制备光学纯净的卡托普利及其类似物的方法。该分辨过程通过S-保护的卡托普利及其前体的分数结晶实现，这些衍生物有用之处在于它们（1）易于从新前体制备，（2）可分离到其光学纯净的对映异构体种类，（3）可转化为对应于药理活性抑制剂及其类似物的非衍生的对映异构体种类。此外，本文还提供了制备这些衍生物及其前体的新方法。此外，还描述了这些新的衍生物及其前体。

  公开号：

  US05166361A1

文献信息

• Methods for preparing captopril and its analogues
  申请人：Sepracor, Inc.

  公开号：US05166361A1

  公开（公告）日：1992-11-24

  This invention relates to novel methods for converting a diastereomeric mixture of S-protected derivatives of an orally active inhibitor of an angiotensin-converting enzyme (ACE) and its analogues into its separate optically resolved diastereomeric components. Specifically the invention relates to methods for the preparation of optically purified captopril and its analogs from racemic precursors. This resolution process is achieved through the fractional crystallization of S-protected derivatives of captopril and its precursors, which derivatives are useful for the reason that they are (1) easily prepared from novel precursors, (2) resolvable to their optically purified stereoisomeric species and (3) convertible to non-derivatized stereoisomeric species which correspond to the pharmacologically active inhibitor and its analogues. Novel methods for preparing the derivatives and their precursors are also noted herein. In addition, the novel derivatives and their precursors are also described herein.

  本发明涉及一种将口服血管紧张素转化酶（ACE）抑制剂的S-保护衍生物及其类似物的对映异构体混合物转化为其单独的光学分辨对映异构体组分的新方法。具体地，本发明涉及从外消旋前体制备光学纯净的卡托普利及其类似物的方法。该分辨过程通过S-保护的卡托普利及其前体的分数结晶实现，这些衍生物有用之处在于它们（1）易于从新前体制备，（2）可分离到其光学纯净的对映异构体种类，（3）可转化为对应于药理活性抑制剂及其类似物的非衍生的对映异构体种类。此外，本文还提供了制备这些衍生物及其前体的新方法。此外，还描述了这些新的衍生物及其前体。
• Derivatives and precursors of captopril and its analogues
  申请人：Sepracor, Inc.

  公开号：US05237073A1

  公开（公告）日：1993-08-17

  This invention relates to novel S-protected derivatives of an orally active inhibitor of an angiotensin-converting enzyme (ACE) and its analogues, which derivatives are useful for the reasons that they are (1) easily prepared from novel precursors, (2) resolvable to their optically purified stereoisomeric species and (3) convertible to non-derivatized stereoisomeric species which correspond to the pharmacologically active inhibitor and its analogues. Consequently, this invention also relates to the novel precursors. Novel methods for preparing the derivatives and their precursors are also noted herein. In addition, methods for converting the derivatives to the resolved de-derivatized stereoisomeric species of the ACE inhibitor and its analogues are described.

  本发明涉及一种口服的血管紧张素转化酶（ACE）抑制剂及其类似物的新型S-保护衍生物，这些衍生物有以下优点：（1）易于从新型前体制备，（2）可分离其光学纯异构体，（3）可转化为对应于药理活性抑制剂及其类似物的非衍生立体异构体。因此，本发明还涉及新型前体，以及制备这些衍生物和前体的新方法。此外，还描述了将这些衍生物转化为已分离去衍生的ACE抑制剂及其类似物立体异构体的方法。